Integrated Drug Discovery at Jubilant Biosys: Helping Biotechs achieve differentiated outcome with our 4D approach  
Jubilant Biosys
January 22, 2020
11 am to 12 pm EST



Webinar Description:

Drug discovery is a complex process that requires cross functional scientific expertise and knowledge in disease biology. Jubilant’s understanding of disease biology is constantly evolving with every emerging literature and new technologies are enabling investigations that were deemed unviable in the past. One has to cautiously and continuously apply this knowledge in the drug hunting process to be successful in drug discovery in a timely manner.

Jubilant Biosys has invested in Science and Technology and we have built an Integrated Drug Discovery site with cross functional expertise in discovery informatics, computational chemistry, medicinal chemistry, protein sciences, structural biology, assay biology, disease biology & pharmacology, DMPK & toxicology. We work on a variety of therapeutic areas including metabolic disorders, inflammation, oncology & Pain and we have conducted more than 75+ Integrated Drug Discovery programs with Biotech and Pharma partners till date. Our specialization is small molecule drug discovery and we have technology platforms to prosecute proteins, DNA, and RNA as drug targets.

Our customers include VC funded early stage Biotechs, mid-size and large Pharma and Biotechs. We engage with our customers from early stage target ideation, all the way through IND enabling studies to deliver a candidate. The Webinar will focus on the Integrated Drug Discovery capabilities of Jubilant Biosys and specifically, we will talk about our experience on working with Biotech and Pharma partners on Target to Candidate drug discovery programs.

This educational webinar will be helpful for those involved with:

  • Make your resources do more for you by benefiting from Jubilant’s capabilities in executing small molecule research programs.
  • Understand the relevance of cross-functional interactions for integration and acceleration of your programs.
  • Choose a Partner who helps overcome project hurdle through intellectual contribution.


Saravanakumar Dhakshinamoorthy image

Saravanakumar Dhakshinamoorthy, PhD
Vice President, Discovery Biology
Jubilant Biosys Limited

Saravanakumar (SK) has 20 years of experience in discovery biology & pharmacology. SK has worked at leading drug discovery organizations and has held positions of increasing responsibility. SK has managed drug discovery collaborations with big pharma and biotech companies across United States, Europe & Asia that has led to candidate compounds for clinical development.


Cost: No Cost!